SEC Tracker
Get the app

PMV Pharmaceuticals PMVP

PMV Pharmaceuticals appoints Dr. Eckler to board

Form
8-K
Filed
Importance
Major
  1. Dr. Matthew Eckler appointed on Oct 1, 2026
  2. Serves until 2029 Annual Meeting
  3. Received 84,000 stock options
  4. Compensation includes $40,000 annual cash

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when PMV Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
  2. Cue Biopharma CUE public float $52M, Jun 30, 2025
  3. Fitlife Brands FTLF public float $51M, Jun 30, 2025
  4. Immucell ICCC public float $51M, Jun 30, 2025
  5. iBio IBIO public float $58M, Dec 31, 2025